Neonatal health testing from Randox: what to expect after birth
Neonatal health testing from Randox: what to expect after birth
It’s been almost a month since the Duke and Duchess of Cambridge welcomed Prince Louis into the Royal Family, and as reported it was a natural birth with no complications.
But caring for a newborn baby in the first few hours of its life isn’t quite as simple as it may have seemed in the picture-perfect media coverage of Kate and William introducing their third child to the world for the first time.
Behind the doors of the hospital maternity ward, doctors and nurses are busy carrying out a wealth of tests to ensure the health of the neonates in their care. Because the time immediately following a baby’s birth is crucial for their development in the coming months.
Newborn babies are particularly at risk for some diseases because their immune systems aren’t yet developed enough to fight bacteria, viruses and parasites. Just a few minutes after a baby’s arrival, they will be poked, pricked, measured, tested, examined, cleaned and swaddled – all in the name of making sure they are – and importantly, remain – healthy.
The first test to be conducted is usually an Apgar score – a simple assessment of how a baby is doing at birth, to help determine whether they are ready to meet the world without additional medical assistance. Based on heart rate, colour, reflex response, activity, muscle tone and breathing, the Apgar score ranges from zero to ten, with anything above seven or above being considered a healthy score. Babies with a score below seven will have their issues addressed – it could be something as simple as moving them to a warmer room until they are able to maintain their own body temperature, or clearing their nose and mouth for more efficient breathing.
The baby is then weighed and measured, and may be given antibiotic eye ointment to prevent infections, and vitamin K to prevent clotting problems.
They will also have their pulse, abdomen, genitals, fingers and toes examined, and their Ballard score taken. This takes into account head circumference, chest circumference and length, to confirm gestational age.
A paediatrician will then assess risk factors for infection and ensure that the baby is feeding well. They will also check for jaundice, which causes yellowish skin when bilirubin, a compound formed by the liver, isn’t being broken down properly.
Neonatal jaundice is extremely common, because during the first week of their life nearly every newborn develops a somewhat elevated bilirubin level, which could potentially lead to jaundice. And the good news is, that if diagnosed early, jaundice can easily be eradicated, by exposure to a specialist light that can help break down bilirubin.
At Randox, we offer a test for bilirubin to diagnose and monitor newborn jaundice, which, in rare cases if left untreated, can lead to brain damage. Early, accurate diagnosis is therefore imperative and so to ensure the precision of the bilirubin tests, Randox also offers Acusera Bilirubin Elevated Quality Control.
The baby will also have their heel pricked for a variety of metabolic conditions including sickle cell anaemia, which causes red blood cell destruction. The Randox test for haptoglobin, a protein found in blood plasma, can help to diagnose sickle cell anaemia.
Or if the baby is premature, they will remain in the hospital nursery. Depending on how premature the baby is there will be different types of tests and treatment given, but they will have their temperature, heart rate and respiratory rate closely monitored. These vital signs will be checked regularly for the first few hours of the baby’s life.
So as you can see, within just a few short hours newborn babies are kept incredibly busy. Procedures may vary from one hospital to the other, but one thing is for sure: neonatal tests are vital in determining and protecting the health of babies.
Randox is committed to saving and improving lives – at any age and any stage of life.
Our innovative diagnostic technologies are versatile and easily adapted for use in the paediatric setting – keeping your baby healthy now and into the future.
For more information on neonatal health tests available from Randox, please email randoxpr@randox.com or phone 028 9442 2413
Randox Testing Services | How can a policy form the basis of workplace drug & alcohol testing?
If you work in a company with safety-critical roles it is more than likely that you have some sort of workplace drug and alcohol testing policy in place. Even companies without safety-critical roles are implementing these policies to further ensure the health, safety and wellbeing of their staff.
Employers hold the responsibility to ensure employees are fully aware of the company’s rules, regulations, testing and disciplinary procedures.
The policy itself holds vital importance, providing employees with the knowledge of the standards expected of them, whilst educating themselves with information provided in a written comprehensive manner.
The importance of implementing a policy
The most important element of a workplace drug and alcohol testing policy is SAFETY. Drug and alcohol use increases the probability of workplace accidents occurring. Studies have found that employees who have alcohol problems are 2.7 times more likely to have an accident whilst at work. The main issues associated with substance misuse relate to:
- Absenteeism – it’s estimated that 17 million days of work are lost per year due to substance misuse.
- Low productivity levels – employees may reduce output in different tasks and become de-motivated.
- Inappropriate behaviour – some cases of substance abuse may lead to crime.
- Aggressive behaviour towards others – resulting in loss of employment / convictions
It’s evident that many who suffer from drug & alcohol abuse are in employment. Studies show 25% of those in employment were registered drug addicts with 3.3% of all adults aged 16-59 classified as frequent users.
Significant issues such as these provide growing concerns for employers to implement a workplace drug and alcohol policy, to ensure the welfare of each member of staff is considered. Under the Health & Safety Act 1874, employers have a responsibility to ensure the safety of their employees is fully met in order to maintain standards.
The importance of a workplace policy for drugs and alcohol can benefit employers by:
- Building relationships with employees by showing there is help and support available.
- Policies can raise awareness of issues in the business and can encourage staff members to take action if needed.
- It can reduce the number of sick employees, reduce staff turnover and increase productivity levels.
Speak with us directly
We understand that the importance of having a policy that suits the specific needs of your company. In order to fully achieve this, we offer a free policy review service, where we will review your company’s existing documentation to gain an understanding of how we can help going forward.
We are delighted to announce we will be attending the Safety & Health Expo 2018. The annual event, running from 19th – 21st June and held at the Excel London, is the UK’s largest health and safety event with over 13,500 national and international key industry professionals across construction, manufacturing, government and consulting.
By attending this prestigious event we hope to engage with a range of stakeholders to discuss how our drug & alcohol testing services can have a positive impact on your employees and business.
If you are attending this event and would like to speak with us, please stop by our stand M410 to speak with one of our experts.
Alternatively, if you would like to arrange a meeting with us prior to the event, please email us: testingservices@randox.com, and quote Safety & Health Expo 2018 at the beginning of your message.
For more information on workplace drug & alcohol testing, visit www.randoxtestingservices.com.
We Are Randox | Ciaran Richardson
What makes Randox the successful, innovative and forward-thinking company it is today are the passionate, hard-working and talented staff we’re lucky enough to call our colleagues.
Our staff are our best asset and across every division our team help to save lives – whether it be designing the newest Biochip to test for Alzheimer’s disease, developing the latest software for use in hospitals and universities or managing our global offices, to ensure our pioneering health technologies make their way across the world to where they are needed the most.
Our headquarters are in Northern Ireland, but we have teams based all over the world, including in Donegal, Ireland, where Dr Ciaran Richardson heads up the Research and Development Team.
We sat down with Ciaran to ask him about his role in Randox, to find out what inspired him to become a scientist, and of course to discover what makes working in Randox Teoranta in Donegal so special.
Ciaran, can you tell us a little bit about your role at Randox Teoranta?
My name is Ciaran Richardson and I am the Research and Development Manager at the Randox Teoranta facility based in Dungloe in County Donegal. I have some operational responsibilities at the facility but I primarily focus on working closely with the Research and Development scientists here. They use unique Randox technologies to develop next-generation diagnostic tests for prevalent human diseases such as stroke, cancer, Alzheimer’s disease, chronic kidney disease, gastrointestinal disorders and thyroid disease. What’s particularly interesting is that we don’t focus exclusively on human conditions. The team at Randox Teoranta is constantly evaluating new technologies and methodologies with a view to continuous evolving how we approach our work and we are currently developing veterinary diagnostic tests.
What kind of research takes place at Randox Teoranta?
More than 50% of the workforce in Dungloe are employed in Research and Development positions. Our teams of R&D scientists are using a world-first technology that is unique to Randox called Biochip Array Technology. This technology allows you to place multiple diagnostic tests on a single biochip and this can then be used to test for many different biomarkers in a sample of blood. This is in stark contrast to traditional diagnostic methods that perform one test at a time on a sample of blood.
But it’s not only scientific research that we undertake at Randox Teoranta. It is critically important that our hardware keeps pace with the new diagnostic tests that we are developing. We have a highly skilled team of R&D Engineers that are developing next generation diagnostic analyser systems for Randox. We have electronic, mechanical, embedded systems and software disciplines all working together to develop new analysers that enable effective and accurate reporting of results from our diagnostic tests.
We also have significant manufacturing capabilities at the site in Dungloe. We have a dedicated department for manufacture of the Randox biochips and a further department for manufacture of the Randox family of analyser systems.
What does a typical day look like for you?
I manage a broad spectrum of R&D projects so my days can be quite varied. I could be meeting with our different scientific teams or managing ongoing projects that we have with various collaborators throughout the world. R&D is a rewarding but challenging field and it is very important that we react quickly to problems as they arise. I therefore spend lots of my time meeting with the scientists to review data so that we can make strategic decisions to move things forward as efficiently as we can.
Did you always want to be a scientist?
The short answer is no. My father was a businessman and my mother was a teacher, but she said I didn’t have the patience to be a teacher. I must admit she was probably right! My passion for science came to the fore when I studied Biology, Chemistry and Mathematics at Pobalscoil Chloich Cheannfhaola in Falcarragh. I went on to study Biotechnology at the National University of Ireland, Galway, and then undertook my PhD studies in Cancer Research at the University of Wales College of Medicine in Cardiff. I then spent the next five and a half years working at the MRC Protein Phosphorylation Unit at the University of Dundee.
When our first daughter was born in Dundee we decided we wanted to move back to Donegal but my job prospects there, as a scientist, were slim. I did, however, apply for a role in Randox’s County Antrim headquarters which I was delighted to get. 18 months later, I was asked to become the R&D manager at a brand new Randox site in West Donegal. The rest, as they say, is history. Science can be a challenging career but it is extremely rewarding to think that the work we do at Randox Teoranta has the potential to not only improve people’s lives, but extend them far beyond expectancy.
What’s your favourite thing about working here?
My drive to work is surrounded by the most fantastic scenery. I feel privileged that I have been provided with an opportunity to return home to west Donegal to take up such a challenging and exciting position in the field of science just 20 minutes from my doorstep in Gweedore.
Working at Randox Teoranta allows me to spend more time with my family as I have such a short commute and I haven’t had to re-settle my family from our native Donegal for me to follow my career dreams. We have four children and a dog so you can imagine how busy things can be! When I get home in the evening I enjoy spending time with my wife and children. I work hard during the week and then the weekend is family time.
Can I find my dream career at Randox Teoranta?
We’re expanding our workforce which means there are plenty of opportunities at Randox Teoranta. From placement student roles to permanent positions, we’re always on the lookout for the right candidates in various different fields – from manufacturing to research and development, administration to mechanical, electrical and electronic design engineering and software development to administration. At Randox Teoranta, we’re involved in world-leading science and technology every day. It’s amazing to think that your dream role in global innovation could be right on your doorstep in beautiful Donegal.
We are delighted that Ciaran has found his dream job with us at Randox in his native Donegal. He is a real asset to our global healthcare company and we’re proud to have him as part of our team.
For more We Are Randox stories about our amazing colleagues, make sure to follow us on Facebook, Instagram and Twitter and follow the hashtag #WeAreRandox.
For current vacancies in our team, visit careers.randox.com
Take the #TrueAgeChallenge and win a FitBit on each day of the Balmoral Show with Randox Health
Who is the 2018 Balmoral Show’s healthiest person? That’s a question Randox Health is posing at this year’s event, as it announces details of an interactive challenge ahead of this week’s event.
Anyone over the age of 16 can take part by visiting the Randox Health stand and taking part in the True Age Challenge. It involves a Body Composition Analysis (BCA) machine which assesses 25 different areas of your body including the ratio of muscle to fat, bone density, hidden visceral fat and cellular hydration levels.
But it’s the reveal of a person’s ‘true’ or metabolic age that can really leave people amazed!
The #TrueAgeChallenge winner will receive a FitBit Blaze each day of the Balmoral Show. They will either be the single person with the greatest difference between their body age and ‘true’ age as determined by the BCA, or if there are multiple people with the same age difference, they will be entered into a draw.
Peter FitzGerald, Managing Director of Randox, commented:
“The True Age Challenge is a novel way to highlight the importance of finding out the current state of your own personal health. For many people, talking intimately about our health can be taboo so we’re working to start that crucial conversation that sparks a desire within people to take control of their health. Our ambition is to help people extend their lives, and live healthier for longer.”
Local well-known names, Young Farmers’ Clubs of Ulster President James Speers and Downtown Radio presenter Kirstie McMurray are looking forward to taking part.
James Speers, President of the Young Farmers’ Clubs of Ulster, said of the challenge:
“It’s shaping up to be another great year at Balmoral and the Randox Health True Age Challenge is a fantastic way for people to get a quick overview of their health while at the show. I’m looking forward to partaking in the challenge – hopefully I’ll be pleasantly surprised!”
Downtown Radio and Downtown Country presenter, Kirstie McMurray, commented:
“When I heard about the Randox Health True Age Challenge I was keen to have a go! I’ve been going to a gym regularly for a year now and I’m interested to see the difference that has made to my health. Fingers-crossed I’m a few years ‘younger’ than my real age!”
Randox Health will be on stand A7 throughout Balmoral Show 2018.
Follow Randox Health’s Facebook, Twitter and Instagram to find out about our #TrueAgeChallenge and daily winners.
For more information about the #TrueAgeChallenge, please contact Randox PR on 028 9442 2413 or email RandoxPR@randox.com
Randox partners with Liverpool Guild of Students for their annual awards ceremony
Randox were proud to sponsor four awards at the Liverpool Guild of Students Awards 2018 which took place on Friday 27th April in the city’s Mountford Hall. Now in its tenth year, the prestigious occasion recognises individuals or groups who have gone above and beyond the call of duty to help fellow students and the wider community while improving student experience at the University of Liverpool.
The ceremony was attended by 300 students nominated from Liverpool Guild of Student’s 22,000 student member body, along with key university staff members. Liverpool University is privileged to enjoy such a vibrant and active student culture in the city which made for tough competition in each of the awards categories.
The categories sponsored by Randox were in the Development category block;
Campaign of the Year – the Liverpool University Marine Biology Oceanography and Ecology Society won this award after they developed a campaign to reduce plastic impact on-campus as well as helping the general public to become more knowledgeable on the issue.
The Development Award – Congratulations to the Liverpool Paediatric Society who received this award. The society has fully committed to providing high quality academic, skills based sessions for their members. As well as fundraising for nominated charities throughout the year, they also provide excellent opportunities for members to learn new skills to help them both in their studies and future careers.
The Innovation Award – the National Hindu Students’ Forum Liverpool won the award for innovation after they built on the success of their previous committee members and raised over £400 for MIND by transforming a once small-scale event, Asha, into a large-scale event with stalls, raffles, performances and a three course meal.
The Challenge Award – the Feminist Society at the University of Liverpool has promoted inclusivity and broadened the reach of the Guild outside of the university campus. They have hosted a wide variety of fundraisers and club nights not only to raise funds for charities but also to educate attendees on sexual violence.
Dr. Peter FitzGerald, Managing Director of Randox, commented on the sponsorship;
“Through our own world-leading research and development in the field of health diagnostics, we are making a difference both locally and worldwide to improve health and extend lives. Development is one of the most fundamental areas in the modern era as we move forward, break boundaries and expand in to new territories and technologies in health research and diagnostics.
“Our sponsorship of the Development category at the Liverpool Guild of Students Awards – the Campaign of the Year, Innovation, Challenge and Development awards – signals our commitment to the future of research and the importance of both new ideas and talent for the future of science and beyond.”
Glen Whitcroft, Media Sales Manager at the Liverpool Guild of Students, said;
“We were incredibly proud of the achievements of our students. The positive difference they have made to their campus and communities is immeasurable and having a world-leading company such as Randox recognising their hard work by sponsoring four of our awards at the Liverpool Student Guild last week was a privilege. Randox is a company well-known for its encouragement of young talent through its second-to-none placement and graduate opportunities in a variety of disciplines from science and technology to engineering, marketing and even graphic design. We’re delighted to partner with a company who places such value on the importance of student and graduate positions.”
For more information on the Liverpool Guild of Students Awards available please email randoxpr@randox.com or phone 028 9442 2413.
Is Biomarker Multiplexing the future of kidney disease screening?
Chronic Kidney Disease (CKD) is both a cause and a consequence of cardiovascular diseases, and is an increasing burden on global health. As diabetes, obesity and hypertension incidences continue to rise and the world’s population steadily ages, CKD’s prevalence is already estimated to be between 11% and 13% globally for all five KDOQI stages, with a majority in Stage 3 (about 90% of all stages).
With early stages of CKD being asymptomatic and current diagnostic tools (proteinuria determined by albumin to creatinine ratio and decreased renal function estimated from GFR using the CKD-EPI equation) are insufficiently sensitive to detect most cases up to stage 3, it is likely that the true prevalence of CKD is still underestimated. Therefore the need to improve both early diagnostics and overall CKD outcome is all the more critical.
Accordingly, biomarker research has been intense in the field of renal disease for at least 10 years with a number of promising candidates emerging, some now well-known by specialists: Cystatin C, NGAL or KIM-1 for example.
However, further novel biomarkers, assessed in combination using a properly developed multiplex assays can allow superior insight into CKD than what their individual performance could achieve. This also largely stems from selecting the markers that are indicative of complementary mechanisms that contribute to the development of CKD.
When assayed together from a single serum sample and after combinatorial analysis has been applied, these biomarkers can open new avenues in the management of CKD, such as proper diagnosis of the condition from Stage 1, clear differentiation between stages and monitoring of the progression pace of the disease. Early screening of patients at risk of CKD is now within reach and it is expected that its systematic use will have a profound impact on health system economics.
Another area of interest in renal research is Acute Kidney Injury (AKI) which may arise as a result of cardiac surgery and can subsequently lead to CKD. AKI detection is also of significant interest in the field of drug development, where early stage toxicity is still a large cause of new drug marketing withdrawal. Hence selecting and qualifying kidney tissue damage biomarkers, and assembling them into a multiplex panel is a key priority to those involved in early stage clinical trials.
An AKI panel has been worked out using the same principles as those used in the development of the CKD panel: high individual diagnostic value and multiple, independent cellular targets. This panel is now ready for final clinical qualification and will be one of the first of several organ-targeted safety panels aiming to become standard for drug induced toxicity screening.
It is key to the adoption of multiplex testing that proper validation guidelines be published and that careful, matrix-based validation data is made available to potential users. It is essential that multiplexed testing comes to the front line of testing in the field, so it can deliver to its full potential and start translating into public health improvement and cost savings. Technology is ready, let’s make a start!
Dr Claire Huguet
Randox Biosciences – Head of Biomarkers
For further information about kidney disease screening from Randox Biosciences, please contact randoxpr@randox.com
Neonatal health testing from Randox: keeping your baby healthy now and into the future
Most newborns enter the world healthy. But sometimes, infants develop conditions that require medical tests and treatment. Newborns are particularly at risk for some diseases, and in particular infections, because their immune systems aren’t developed enough to fight bacteria, viruses, and parasites.
At Randox we offer a number of accurate and reliable tests capable of detecting illnesses in newborn babies, enabling early medical intervention to allow for the best possible outcome for the baby.
Testing for Jaundice with Randox Bilirubin
In the routine care of newborns, a test for bilirubin is commonly conducted.
Bilirubin is formed by the breakdown of haemoglobin in the spleen, liver and bone marrow. It travels to the liver where it is secreted into the bile ducts as bile, and stored in the gallbladder where it is later released into the small intestines for digestion.
Increased levels of bilirubin within the body are associated with a condition called jaundice, which occurs in toxic or infectious diseases of the liver. The most common symptom of jaundice is a yellow pigmentation of the skin.
Elevated levels of bilirubin may also arise as a result of an obstruction in the bile duct or gall bladder, as a result of haemolysis (the destruction of red blood cells), or by the liver not actively treating the haemoglobin it is receiving.
Therefore the Randox Bilirubin test is essential in the screening, monitoring and diagnosis of hepatic (liver function) disorders and jaundice in newborn babies.
Neonatal jaundice, otherwise known as hyperbilirubinemia, is extremely common in babies, because nearly every newborn develops a somewhat elevated bilirubin level during the first week of life.
Side effects may include excess sleepiness or poor feeding, but in some more extreme cases babies may experience seizures, cerebral palsy, delayed intellectual development, or physical abnormalities.
Early and accurate detection is therefore extremely important – making bilirubin testing fundamental. To ensure the precision of the bilirubin tests conducted in paediatric testing, Randox also offers Acusera Bilirubin Elevated Quality Control.
Monitoring the destruction of red blood cells with Randox G-6-PDH
Glucose-6-Phosphate Dehydrogenase (G-6-PDH) is an enzyme located on the X-chromosome, and so is found in every bodily cell as soon as a baby is born.
G-6-PDH is involved in the normal processing of carbohydrates and plays a critical role in red blood cells, protecting them from damage and destruction. Depleted levels of G-6-PDH can therefore cause red blood cells to become particularly vulnerable to haemolysis. G-6-PDH deficiency, which causes rapid heart rate, shortness of breath, excess tiredness, and mild to severe jaundice in new-borns, affects more than 400 million people globally.
During a baby’s new-born screening, a test for the G-6-PDH enzyme will be conducted to check for this deficiency disorder. Early diagnosis is imperative, as untreated haemolysis can result in haemolytic anaemia.
Genetic Disease Screening with Randox Copper
Copper is an essential mineral in human nutrition, and is mainly found in the brain, liver, kidneys, heart and skeletal muscle.
It aids in some of the key bodily functions including the production of red blood cells, the maintenance of nerve cells and the immune system, and the formation of bone and connective tissue. A deficiency in this mineral can therefore result in bone abnormalities or fractures in premature babies.
Copper deficiency can also be caused by an inherited disorder called Menkes Disease. Affecting approximately 1 in 100,000 children worldwide, this condition is characterised by sparse, kinky hair; failure to gain weight and grow at the expected rate, and deterioration of the nervous system.
The first signs of Menkes Disease – curly, sparse, coarse, dull, and discoloured hair – usually first develop at 2-3 months of age and therefore monitoring copper levels in babies is a way to catch this rare condition at the earliest possible opportunity.
Testing for Lupus with Randox Complement C4 and Complement C3
Another condition which can affect newborn babies is neonatal lupus, which occurs when the mother’s antibodies affect the foetus. A rare condition, it is an autoimmune disease caused by the body’s immune system attacking its own tissues and organs.
The Complement C4 and Complement C3 proteins, which play an important role in eliminating certain infections, can be used as biomarkers in the diagnosis and monitoring of lupus. Complement C4 deficiency is commonly associated with lupus, as the protein is required to clear damaged cells, promote inflammation, and attack pathogens.
Although there is no cure for lupus at present, the condition is very treatable and usually responds well to a number of different types of medication – especially when treatment is started in the early stages of the disease.
Early diagnosis is therefore imperative, and the Randox Complement C4 and Complement C3 tests can help to diagnose babies with lupus at the earliest possible stage. Randox also offer Acusera Immunology controls.
Monitoring a baby’s anti-infection defences with Randox IgA
IgA (immunoglobulin A) is an antibody present in the cells of the immune system, and plays a crucial role in the immune function of mucous membranes including tears, saliva, and sweat. It is also present in colostrum, often referred to as ‘liquid gold’, which is the first secretion from the mammary glands after giving birth.
It’s the IgA in colostrum and milk that is important in neonatal protection against infection and it is therefore imperative to monitor the levels of this antibody to make sure your baby is receiving the anti-infection defences he or she requires.
Testing for allergic reactions with Randox IgE
IgE (immunoglobulin E) is an antibody released by the immune system as a defence mechanism when it believes the body is at risk. IgE determinations are therefore used as an aid in the diagnosis of allergic diseases.
In babies, an allergen-specific IgE test may be done to look for some kinds of allergies, including food, animal dander, pollen, mould, medicine, dust mites, or insect venom.
Increased concentrations of IgE will confirm that an allergic response has occurred, facilitating further investigation as to the specific allergy present.
Testing for bacterial infection with Randox CRP
C-reactive protein (CRP) is an acute phase protein found in blood plasma and produced by the liver. The concentration levels of CRP increase in response to cytokines which are produced by white blood cells during inflammation, infection and tissue injury.
Testing for this protein can therefore be used in the detection of bacterial infections in neonates – enabling antibiotic prescription and a speedy recovery. If infection is identified, CRP can also be used to monitor treatment response or identify neonatal septicaemia.
Randox is committed to saving and improving lives – at any age and any stage of life.
Our innovative diagnostic technologies are versatile and easily adapted for use in the paediatric setting – keeping your baby healthy now and into the future.
For more information on neonatal health tests available from Randox click here or email randoxpr@randox.com or phone 028 9442 2413
Randox Food Diagnostics offers innovative multiplex technology for mycotoxin screening within varieties of farmed crops
Mycotoxins are poisonous chemical compounds produced by certain fungi. There are many such compounds, but only a few of them are regularly found in food, farmed crops and end product animal feeds. Since they are produced by fungi, mycotoxins are associated with diseased or mouldy crops. Those that do occur in food may have an impact on livestock and the health of humans and have been associated with conditions such as asthma, respiratory infections and chronic fatigue. The main causes of mycotoxins within stored grains are when the grain is damp, damaged or cracked and kept in insufficient storage conditions.
The formation of mycotoxins is climate-dependent, with temperature and moisture levels directly impacting fungal growth. Evidence shows that climate change is causing increasing temperatures and altered rainfall patterns. Additionally, extreme weather incidents have increased. As a consequence of these changes, increased levels of mycotoxins have been observed in some European crops.
Mycotoxins occur, and exert their toxic effects, in extremely small quantities in foodstuffs. Their identification and quantitative assessment therefore generally require sophisticated sampling, sample preparation, extraction, and analytical techniques. Under practical storage conditions, the aim should be to monitor for the occurrence of fungi. If fungi cannot be detected then there is unlikely to be any mycotoxin contamination. The presence of fungi indicates the potential for mycotoxin production, and the need to consider the fate of the batch of commodity affected.
In order to help the industry Randox Food Diagnostics developed the Evidence Investigator analyser. The Investigator uses Biochip Array Technology (BAT), a technology that was developed by Randox, to detect multiple residues (up to 45) from a single sample. Within farmed crops Randox Food Diagnostics provide testing for different matrices such as: Maize silage, maize, Barley, grass seed, rice, wheat, oats, soya, DDGS, rapeseed as well as livestock and pet foods including premixed feed.
Randox Food Diagnostics offer a mycotoxin screening array on Biochip called Myco 10 which can detect 10 mycotoxins per sample including aflatoxins G1/G2 & B1/B2, ergot alkaloids, fumonisins, paxilline, ochratoxin A, diacetoxyscirpenol, deoxynivalenol (DON), T2 toxin & zeralenone. Also offered is a range of ELISA test kits including ergot alkaloids.
Randox Food Diagnostics is a regular participant in the FAPAS proficiency testing scheme which provides an independent check of a laboratory’s procedures to ensure the delivery of quality results. To read our study on: Biochip Array Technology for the reliable performance of multi-mycotoxin determination in animal feed materials” click here: http://www.randoxfooddiagnostics.com/docs/default-source/randox-fd/posters/bat-mycotoxins-in-animal-feed-materials.pdf?sfvrsn=4
For more information on our arrays for mycotoxins please visit the website: http://www.randoxfood.com/matrices/mycotoxins or contact us via email at: info@randoxfooddiagnostics.com
The Evidence Series: What is it and how is it changing the diagnostic landscape forever?
Having developed the patented Biochip Array Technology following £250 million investment in diagnostic research and development, we needed a platform that allowed Biochip Array Technology capabilities to be showcased. Step forward the Evidence Series.
The series includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser has been designed and built with boundary pushing engineering, to ensure financial, labour and time savings for the end user.
Have a read below of the overview of each analyser in the Evidence Series
Evidence Evolution
The world’s first fully automated random-access biochip testing platform, the Evidence Evolution is the world’s most advanced immunoanalyser. With the capability to process up to 2,640 tests per hour, the Evidence Evolution offers complete system integration, as well as the most comprehensive test menu on the market.
Evidence
As the world’s first Biochip Array Technology system, the Evidence immunoanalyser has revolutionised laboratory screening worldwide. With the capability to process 3,960 tests per hour and a sample capacity of 360, the Evidence is ideal for use in a high throughput laboratory.
Evidence Investigator
The Evidence Investigator is a compact, semi-automated benchtop immunoanalyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, toxicology and food diagnostics. The Evidence Investigator boasts a throughput of up to 2,376 tests per hour, offering efficiency without compromising on accuracy.
Evidence MultiSTAT
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. With a three-step process and results generated in less than 20 minutes, the Evidence MultiSTAT is an ideal solution for those with no knowledge of laboratory procedures and offers a throughput of up to 132 tests per hour.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on any of the Evidence Series analysers, please visit https://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
Randox / Bosch partnership delivers game-changing device in fight against antibiotic resistance
A partnership between Randox Laboratories, the UK’s largest manufacturer of in-vitro diagnostics, and the German technology giant Bosch is changing the way doctors will treat patients with antibiotics, with the launch of a revolutionary product – the Vivalytic.
It’s estimated that 20% of antibiotics currently prescribed are unnecessary, and fuel the growing threat of global antibiotic resistance. This threatens the ability to treat common infectious diseases, and a growing number are becoming harder, and in some cases impossible, to treat. The World Health Organisation warns that without action, we are heading towards a post-antibiotic era.
This problem is being addressed by the Vivalytic. The result of a decade of R&D, it is an intuitive point-of-care analyser that, depending on the complexity of the test, will deliver results from 30 minutes: enabling doctors to select the right course of therapy faster than before. In some cases, this will be life-saving.
The first tests available on the Vivalytic are Randox’s panels for respiratory and sexually-transmitted infections*.
Using Randox’s patented Biochip Array Technology, the Respiratory Multiplex Array simultaneously reports on 22 viral and bacterial pathogens including Bordetella pertussis and parapertussis which causes whooping cough – without the need for secondary or confirmatory testing to inform clinical treatment decisions. The STI array enables the detection of 10 STIs from a single sample. Every day more than 1 million STIs are acquired, and many have mild if any symptoms at all. Identifying these infections correctly first time reduces the misuse of antibiotics and supports their targeted use.
The Managing Director of Randox Dr Peter FitzGerald commented:
“Antibiotic stewardship is a critical issue which we all have a responsibility to embrace and drive forward. This partnership is ideal, combining our expertise in molecular laboratory diagnostics with Bosch’s cutting-edge engineering. The Vivalytic is a game-changer for clinicians and patients: never before has there been this level of accessibility to this range of molecular diagnostics.”
Marc Meier, General Manager of Bosch Healthcare Solutions, a wholly owned subsidiary of Bosch Group, said:
“We are enthusiastic about having gained Randox as the first partner on our platform with two initial panels available from the start. It´s the beginning of jointly expanding the Vivalytic test portfolio for our clients. In this partnership the core competencies of Bosch in automation, miniaturization, and networking are complemented by Randox’s expertise in developing and commercializing innovative diagnostic solutions.”
Vivalytic and the panels will be presented to industry professionals for the first time at the ECCMID 2018 Congress in Madrid, Spain, in hall 10, booth 55A between 21st – 24th April.
*CE pending and FDA planned.
For further information about the Vivalytic, please contact randoxpr@randox.com